Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae.
AM-1155, a novel fluoroquinolone, exhibited potent activity against Streptococcus pneumoniae, including penicillin-resistant strains; the MIC90 for 48 clinical isolates was 0.25 mg/L. The antibacterial activity of AM-1155 against S. pneumoniae was higher than that of levofloxacin (MIC90 1 mg/L) and comparable with that of sparfloxacin. The MIC90s of penicillin G and erythromycin were 2 and > 4 mg/L, respectively. AM-1155 showed no cross-resistance to penicillin or erythromycin. For experimental murine pneumonia with S. pneumoniae intermediately resistant to penicillin, oral administration of AM-1155 showed efficacy higher than that of levofloxacin and equal to that of sparfloxacin. The efficacy of AM-1155 was also equal to that of subcutaneous penicillin G administration at the same dosage.
Tomizawa
H
H
Department of Microbiology, Toho University School of Medicine, Tokyo, Japan.
Tateda
K
K
Miyazaki
S
S
Yamaguchi
K
K
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance / Q000502:physiology; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011008:Pneumococcal Infections / Q000188:drug therapy*; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D015996:Survival Rate
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D010879:Piperazines; D015363:Quinolones; D000077734:Gatifloxacin